Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seeing the value in observational studies

Executive Summary

Safety signals identified in observational studies require confirmation but provide important information about drug use in a real-world setting, according to a pair of opinion pieces in the Nov. 23 issue of the New England Journal of Medicine; both articles addressed Bayer's failure to disclose a large observational study on its drug Trasylol before a recent advisory committee review (1"The Pink Sheet" Oct. 2, 2006, p. 25). "Although observational studies cannot be definitive...they can provide important new safety information that can direct further scientific and regulatory actions - if their findings can be confirmed," Cardio-Renal Drugs Advisory Committee chair William Hiatt (University of Colorado) said. Jerry Avorn (Harvard Medical School) advises care with application of epidemiological research techniques, and argues that transparency of study methods and raw data are critical to interpreting results that are confounded in such uncontrolled studies...

You may also be interested in...



Trasylol Safety Review Raises Questions About Role Of Observational Data

FDA continues to grapple with the relative benefits of observational data and randomized controlled trials to evaluate drug safety

Pfizer COVID-19 Vaccine Trial Diversity Slips As Enrollment Rises, Unlike Moderna

Trial diversity is among the issues that stakeholders worry could hinder vaccine uptake.

Health And Wellness Trademark Review 8 September, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel